Through our numerous events and fundraisers, CNFWJ has raised almost $4 million for NF research on its own behalf and on behalf of other NF-related entities. But we aren’t stopping there. We won’t stop until a cure has been found and we put an end to NF forever.

CNFWJ is dedicated to funding NF research and only to funding research, and so every dollar raised after costs is attributed directly to research endeavors.

To date, in addition to raising well over two million dollars for NF-Related entities, CNFWJ (has/is):

• Currently funding a Postdoctoral Fellowship at the Walker Lab at MGH/Harvard. This research will make historic strides in developing preventative strategies and therapies for NF. The costs of this research include biology reagents, which are used in DNA-related processes and techniques such as DNA sequencing, DNA cloning and mapping, PCR cloning, and more! This funding of the Walker Lab will also enable the acquisition of machinery to amplify DNA which plays a pivotal role in offering researchers a clearer picture of the strand and enhancing their efforts to find a cure for NF.

• Currently funding a ground-breaking gene therapy project at the University of Alabama Birmingham’s Bedwell Research Lab with the assistance of world-renowned scientists like Dr. Robert Kesterson. NF scientists are now testing drug compounds to restore function to a specific type of NF mutations that affects a significant amount of the NF population. If successful, this significant breakthrough in NF genetics research could also have the potential to advance research for various cancers and other diseases.

• Sponsored Clinical Trials Leading to the First NF FDA-Approved Drug. CNFWJ’s first distribution of funds went to furthering clinical trials that has led to the first ever FDA-approved drug (Koselugo) known to reduce tumor size in a significant number of NF pediatric patients with inoperable plexiform neurofibromas.

• Funded Global Collaborative Project on Low Grade Gliomas – CNFWJ was a sponsor for the research by a group of NF experts who analyzed – for the first time in history – a large enough number of specimens of specific NF brain tumors (low grade gliomas – “LGG”). Their work led to an increased understanding of LGGs in children and adults with NF, and to the publication on this subject in the academic journal Neuro-Oncology. The research also resulted in important conclusions that will have implications on treating LGGs and future research on potential therapeutic strategies.

• Hosted A Symposium of specialists from around the country, which led to the publication in the journal Ophthalmology concerning NF ophthalmology issues, including tumors like Jack’s.